Advertisement
Advertisement
U.S. markets open in 3 hours 49 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0450+0.0009 (+2.04%)
At close: 03:56PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall

    Poster Presentation of AC5 Advanced Wound System received award for Highest Scoring Poster Abstract in its categoryFRAMINGHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that its novel product, AC5® Advanced Wound System (“AC5”), was featured at the 2022 Symposium on Advanced Wound Care (SAWC) Fall. AC5 was presented in two poster p

  • GlobeNewswire

    Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall

    Awarded Highest Scoring Poster Abstract in Case Series / Study CategoryFRAMINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that two abstracts highlighting the role of the Company’s AC5® Advanced Wound System (AC5) in clinical cases were accepted for Poster Presentations at the upcoming 2022 Symposium on Advanced Wound Care (SAWC)

  • GlobeNewswire

    Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program

    Significant Milestone in Commercialization Plan Expected to Drive Sales MomentumFRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today confirmed the first shipments of AC5® Advanced Wound System (“AC5”) under the Company’s new reimbursement support program (the “Program”). This development represents a significant milestone in the Company’s

Advertisement
Advertisement